At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology.
Andrew D. Zelenetz, MD, PhD
At the 18th Annual Conference of the National Comprehensive Cancer Network (NCCN), experts presented the latest updates to the NCCN Clinical Practice Guidelines in Oncology. The conference also featured two roundtable discussions that covered topics including cancer treatment costs, disparities in the quality and value of oncology care, the implications of big data in the field of oncology, and personalized cancer care. Here are highlights of the updates and perspectives from key opinion leaders.
Leukemia and Lymphoma
“There are exciting, emerging drugs that could well prove to be revolutionary treatments for chronic lymphocytic leukemia [CLL] and mantle cell lymphoma [MCL] in particular,” said Andrew D. Zelenetz, MD, PhD. “Ibrutinib is an oral agent that inhibits Bruton’s tyrosine kinase… In early studies, this agent has shown a broad range of activity in B-cell lymphoma; however, the responses in CLL, MCL, and Waldenström’s macroglobulinemia have been particularly dramatic. Two other agents demonstrating substantial activity in CLL and MCL are idelalisib, an inhibitor of the delta isoform of PI3K, and ABT 199, a small-molecule inhibitor of the pro-apoptotic Bcl protein. These small-molecule pathway inhibitors likely represent the future of treatment for these diseases.”
“There are only a few changes in the treatment of multiple myeloma, but they’re very important ones,” said Kenneth C. Anderson, MD. “Within the last seven months, two novel agents to treat relapsed and refractory disease have received accelerated approvals from the FDA, based on the results of phase II clinical trials. These additions represent major new treatment options and improved outlook for patients; they promise to extend the progression-free survival and overall survival of patients who previously had no other therapies.”